Allosteric interactions between the antagonist prazosin and amiloride analogs at the human α1A-adrenergic receptor

被引:35
|
作者
Leppik, RA
Mynett, A
Lazareno, S
Birdsall, NJM
机构
[1] Natl Inst Med Res, Dept Phys Biochem, London NW7 1AA, England
[2] MRC, Ctr Collaborat, London NW7 1AD, England
关键词
D O I
10.1124/mol.57.3.436
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It has been demonstrated previously that amilorides can interact with a well defined allosteric site on the human alpha(2A)-adrenergic receptor. In this study, the question was explored as to whether the human alpha(1A)-adrenergic receptor also possesses an equivalent allosteric site. The six amilorides examined strongly increased the dissociation rate of the antagonist [H-3]prazosin from the alpha(1A)-adrenergic receptor in a concentration-dependent manner. With the parent amiloride, the dissociation data were well fitted by an equation derived from the ternary complex allosteric model, compatible with amiloride acting at a defined allosteric site on the alpha(1A)-adrenergic receptor. In contrast, the dissociation data for [H-3] prazosin in the presence of the amiloride analogs were not compatible with the equation derived from a one-allosteric-site model, but could be fitted well by an equation derived from a two-allosteric-site model. However, certain individual parameters could not be resolved. The observed dissociation rate constants increased steeply with increasing amiloride analog concentration, and in some cases the data could be fitted with a logistic equation. The slope factors calculated from such fits were 1.2 to 2.1. It is concluded that the structure-binding relationships of the amilorides at the alpha(1A)- and alpha(2A)-adrenergic receptors are different. The interactions of the five amiloride analogs, but not the parent amiloride, with the alpha(1A)-adrenergic receptor are compatible with the presence of two (but not one) allosteric sites, and is thus more complex than that found for the alpha(2A)-adrenergic receptor.
引用
收藏
页码:436 / 445
页数:10
相关论文
共 50 条
  • [1] Characterization of the allosteric interactions between antagonists and amiloride analogues at the human α2A-adrenergic receptor
    Leppik, RA
    Lazareno, S
    Mynett, A
    Birdsall, NJM
    MOLECULAR PHARMACOLOGY, 1998, 53 (05) : 916 - 925
  • [2] Silodosin: A Selective α1A-Adrenergic Receptor Antagonist for the Treatment of Benign Prostatic Hyperplasia
    Schilit, Sara
    Benzeroual, Kenza E.
    CLINICAL THERAPEUTICS, 2009, 31 (11) : 2489 - 2502
  • [3] Expression of the α1A-adrenergic receptor in schizophrenia
    Clark, Dan A.
    Mancama, Dalu
    Kerwin, Robert W.
    Arranz, Maria J.
    NEUROSCIENCE LETTERS, 2006, 401 (03) : 248 - 251
  • [4] Pharmacology of the Gerbil α1a-adrenergic receptor
    Witt, KM
    Bockman, CS
    Wangemann, P
    Scofield, MA
    FASEB JOURNAL, 2005, 19 (05): : A1082 - A1082
  • [5] The Specific α1-Adrenergic Receptor Antagonist Prazosin Influences the Urine Proteome
    Zhao, Mindi
    Wu, Jianqiang
    Gao, Youhe
    PLOS ONE, 2016, 11 (10):
  • [6] Mechanisms underlying human α1a-adrenergic receptor (α1aAR) desensitization
    Price, R
    Schwinn, D
    FASEB JOURNAL, 1998, 12 (04): : A452 - A452
  • [7] α1A-Adrenergic receptor polymorphism and vascular response
    Sofowora, GG
    Dishy, V
    Landau, R
    Xie, HG
    Prasad, HC
    Byrne, DW
    Smiley, RM
    Kim, RB
    Wood, AJJ
    Stein, CM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) : 539 - 545
  • [8] SUPPRESSION OF EXPERIMENTAL AUTOIMMUNE UVEORETINITIS BY PRAZOSIN, AN ALPHA-1-ADRENERGIC RECEPTOR ANTAGONIST
    RUIZMORENO, JM
    MISIUKHOJLO, M
    THILLAYE, B
    DEKOZAK, Y
    CURRENT EYE RESEARCH, 1992, 11 : 135 - 140
  • [9] Silodosin: A Selective α1A-Adrenergic Receptor Antagonist for the Treatment of Benign Prostatic Hyperplasia Editorial Comment
    Kaplan, Steven A.
    JOURNAL OF UROLOGY, 2010, 184 (04): : 1431 - 1432
  • [10] Design and synthesis of an α1a-adrenergic receptor subtype-selective antagonist from BE2254
    Chiu, George
    Gluchowski, Charles
    Forray, Carlos
    CHEMICAL BIOLOGY & DRUG DESIGN, 2006, 67 (06) : 437 - 439